NKG2D Signaling Leads to NK Cell Mediated Lysis of Childhood AML

Journal of Immunology Research

Volumn 2015, Issue , 2015, Pages

  Schlegel, Patrick ^a   Ditthard, Kerstin ^a   Lang, Peter ^a   Mezger, Markus ^a   Michaelis, Sebastian ^a   Handgretinger, Rupert ^a   Pfeiffer, Matthias ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN CLASS 1; NATURAL KILLER CELL RECEPTOR NKG2D; HLA-E ANTIGEN; KLRK1 PROTEIN, HUMAN; LIGAND; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K;

ACUTE MYELOBLASTIC LEUKEMIA; ANTIGEN EXPRESSION; ARTICLE; BLAST CELL; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY ASSAY; EFFECTOR CELL; FLOW CYTOMETRY; GENOTYPE; HUMAN; HUMAN CELL; NATURAL KILLER CELL; SIGNAL TRANSDUCTION; TUMOR CELL DESTRUCTION; ACUTE MYELOID LEUKEMIA; CASE CONTROL STUDY; CHILD; CYTOTOXICITY; GENE EXPRESSION; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; K-562 CELL LINE; METABOLISM; PATHOLOGY; PHENOTYPE; TUMOR CELL LINE;

CASE-CONTROL STUDIES; CELL LINE, TUMOR; CHILD; CYTOTOXICITY, IMMUNOLOGIC; GENE EXPRESSION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOPHENOTYPING; K562 CELLS; KILLER CELLS, NATURAL; LEUKEMIA, MYELOID, ACUTE; LIGANDS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; PHENOTYPE; SIGNAL TRANSDUCTION;

EID: 84937704630     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2015/473175     Document Type: Article

References (41)

1. G. J. L. Kaspers and U. Creutzig, "Pediatric acute myeloid leukemia: international progress and future directions, " Leukemia, vol. 19, no. 12, pp. 2025-2029, 2005.
2. J. Abrahamsson, N. Clausen, G. Gustafsson et al., "Improved outcome after relapse in children with acute myeloid leukaemia, " British Journal of Haematology, vol. 136, no. 2, pp. 229-236, 2007.
3. J. E. Rubnitz, H. Inaba, R. C. Ribeiro et al., "NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia, " Journal of Clinical Oncology, vol. 28, no. 6, pp. 955-959, 2010.
4. E. Vivier, D. H. Raulet, A. Moretta et al., "Innate or adaptive immunity?The example of natural killer cells, " Science, vol. 331, no. 6013, pp. 44-49, 2011.
5. B. A. Pierson and J. S. Miller, "CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis, " Blood, vol. 88, no. 6, pp. 2279-2287, 1996.
6. F. Tajima, T. Kawatani, A. Endo, and H. Kawasaki, "Natural killer cell activity and cytokine production as prognostic factors in adult acute leukemia, " Leukemia, vol. 10, no. 3, pp. 478-482, 1996.
7. M. W. Lowdell, R. Craston, D. Samuel et al., "Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells, " British Journal of Haematology, vol. 117, no. 4, pp. 821-827, 2002.
8. L. Ruggeri, M. Capanni, E. Urbani et al., "Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants, " Science, vol. 295, no. 5562, pp. 2097-2100, 2002.
9. L. Ruggeri, A. Mancusi, M. Capanni et al., "Donor natural killer cell allorecognition ofmissing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value, " Blood, vol. 110, no. 1, pp. 433-440, 2007.
10. W. Leung, "Use of NK cell activity in cure by transplant, " British Journal of Haematology, vol. 155, no. 1, pp. 14-29, 2011.
11. M. Pfeiffer, M. Schumm, T. Feuchtinger, K. Dietz, R. Handgretinger, and P. Lang, "Intensity of HLA class I expression and KIR-mismatch determine NK-cell mediated lysis of leukaemic blasts from children with acute lymphatic leukaemia, " British Journal of Haematology, vol. 138, no. 1, pp. 97-100, 2007.
12. T. Feuchtinger, M. Pfeiffer, A. Pfaffle et al., "Cytolytic activity of NK cell clones against acute childhood precursor-B-cell leukaemia is influenced by HLA class I expression on blasts and the differential KIR phenotype of NK clones, " BoneMarrow Transplantation, vol. 43, no. 11, pp. 875-881, 2009.
13. E. Lion, Y. Willemen, Z. N. Berneman, V. F. I. Van Tendeloo, and E. L. J. Smits, "Natural killer cell immune escape in acute myeloid leukemia, " Leukemia, vol. 26, no. 9, pp. 2019-2026, 2012.
14. S. Cooley, D. J. Weisdorf, L. A. Guethlein et al., "Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia, " Blood, vol. 116, no. 14, pp. 2411-2419, 2010.
15. S. U. Michaelis, M. Mezger, M. Bornhäuser et al., "KIR haplotype B donors but not KIR-ligand mismatch result in a reduced incidence of relapse after haploidentical transplantation using reduced intensity conditioning and CD3/CD19-depleted grafts, " Annals of Hematology, vol. 93, no. 9, pp. 1579-1586, 2014.
16. P. Lang, K. Barbin, T. Feuchtinger et al., "Chimeric CD19 antibody mediates cytotoxic activity against leukemic blasts with effector cells from pediatric patients who received T-celldepleted allografts, " Blood, vol. 103, no. 10, pp. 3982-3985, 2004.
17. G. J. L. Kaspers, M. Zimmermann, D. Reinhardt et al., "Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the international BFM study group, " Journal of Clinical Oncology, vol. 31, no. 5, pp. 599-607, 2013.
18. L. Oevermann, S. U. Michaelis, M. Mezger et al., "KIR B haplotype donors confer a reduced risk for relapse after haploidentical transplantation in children with all, " Blood, vol. 124, no. 17, pp. 2744-2747, 2014.
19. A. Velardi, L. Ruggeri, and A. Mancusi, "Killer-cell immunoglobulin-like receptors reactivity and outcome of stem cell transplant, " Current Opinion in Hematology, vol. 19, no. 4, pp. 319-323, 2012.
20. W. Leung, R. Iyengar, V. Turner et al., "Determinants of antileukemia effects of allogeneicNKcells, " Journal of Immunology, vol. 172, no. 1, pp. 644-650, 2004.
21. K. L. McQueen, K. M. Dorighi, L. A. Guethlein, R. Wong, B. Sanjanwala, and P. Parham, "Donor-recipient combinations of group A and B KIR haplotypes and HLA class I ligand affect the outcome ofHLA-matched, sibling donor hematopoietic cell transplantation, " Human Immunology, vol. 68, no. 5, pp. 309-323, 2007.
22. G. F. Torelli, N. Peragine, S. Raponi et al., "Recognition of adult and pediatric acute lymphoblastic leukemia blasts by natural killer cells, " Haematologica, vol. 99, no. 7, pp. 1248-1254, 2014.
23. D. Pende, G. M. Spaggiari, S. Marcenaro et al., "Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112), " Blood, vol. 105, no. 5, pp. 2066-2073, 2005.
24. H. R. Salih, H. Antropius, F. Gieseke et al., "Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia, " Blood, vol. 102, no. 4, pp. 1389-1396, 2003.
25. S. Verheyden and C. Demanet, "NK cell receptors and their ligands in leukemia, " Leukemia, vol. 22, no. 2, pp. 249-257, 2008.
26. M. M. Pfeiffer, T. Feuchtinger, H.-M. Teltschik et al., "Reconstitution of natural killer cell receptors influences natural killer activity and relapse rate after haploidentical transplantation of T-and B-cell depleted grafts in children, " Haematologica, vol. 95, no. 8, pp. 1381-1388, 2010.
27. C. J. Chan, M. J. Smyth, and L. Martinet, "Molecular mechanisms of natural killer cell activation in response to cellular stress, " Cell Death and Differentiation, vol. 21, no. 1, pp. 5-14, 2014.
28. J. Hilpert, L. Grosse-Hovest, F. Grünebach et al., "Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses, "The Journal of Immunology, vol. 189, no. 3, pp. 1360-1371, 2012.
29. P. Nowbakht, M.-C. S. Ionescu, A. Rohner et al., "Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias, " Blood, vol. 105, no. 9, pp. 3615-3622, 2005.
30. M. Pfeiffer, G. Seitz, P. Ruck et al., "CD155 is involved inNK-cell mediated lysis of human hepatoblastoma in vitro, " Frontiers in Bioscience-Elite, vol. 3, no. 4, pp. 1456-1466, 2011.
31. M. M. Pfeiffer, M. Schumm, I. Müller, R. Handgretinger, and P. Lang, "IL-15-stimulated CD3/CD19-depleted stem-cell boosts in relapsed pediatric patients after haploidentical SCT, " Leukemia, vol. 26, no. 11, pp. 2435-2439, 2012.
32. P. Schlegel, H.-M. Teltschik, M. Pfeiffer et al., "Long-term IL-2 therapy after transplantation of T cell depleted stem cells from alternative donors in children, " Best Practice and Research: Clinical Haematology, vol. 24, no. 3, pp. 443-452, 2011.
33. H. Fujisaki, H. Kakuda, N. Shimasaki et al., "Expansion of highly cytotoxic human natural killer cells for cancer cell therapy, " Cancer Research, vol. 69, no. 9, pp. 4010-4017, 2009.
34. N. Peragine, G. F. Torelli, P. Mariglia et al., "Immunophenotypic and functional characterization of ex vivo expanded natural killer cells for clinical use in acute lymphoblastic leukemia patients, " Cancer Immunology, Immunotherapy, vol. 64, no. 2, pp. 201-211, 2015.
35. J. S. Miller, "Therapeutic applications: natural killer cells in the clinic, " Hematology/The Education Program of the American Society of Hematology, vol. 2013, no. 1, pp. 247-253, 2013.
36. M. M. Pfeiffer, H. Burow, S. Schleicher, R. Handgretinger, and P. Lang, "Influence of histone deacetylase inhibitors and DNAmethyltransferase inhibitors on the NK cell-mediated lysis of pediatric B-lineage leukemia, " Frontiers in Oncology, vol. 3, article 99, 2013.
37. W.-H. Leung, Q. P. Vong, W. Lin, L. Janke, T. Chen, and W. Leung, "Modulation of NKG2D ligand expression and metastasis in tumors by spironolactone via RXRγ activation, " The Journal of ExperimentalMedicine, vol. 210, no. 12, pp. 2675-2692, 2013.
38. A. Poggi, S. Catellani, A. Garuti, I. Pierri, M. Gobbi, and M. R. Zocchi, "Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate, " Leukemia, vol. 23, no. 4, pp. 641-648, 2009.
39. S. Diermayr, H. Himmelreich, B. Durovic et al., "NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition byNK-cell lines with single KIR-HLA class I specificities, " Blood, vol. 111, no. 3, pp. 1428-1436, 2008.
40. A. Poggi, S. Catellani, A. Garuti, I. Pierri, M. Gobbi, and M. R. Zocchi, "Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate, " Leukemia, vol. 23, no. 4, pp. 641-648, 2009.
41. S. Diermayr, H. Himmelreich, B. Durovic et al., "NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition byNK-cell lines with single KIR-HLA class I specificities, " Blood, vol. 111, no. 3, pp. 1428-1436, 2008.